The therapeutic potential of psilocybin: a systematic review
Expert Opinion on Drug Safety – February 26, 2022
Source: OpenAlex
Summary
A potent hallucinogen, psilocybin, is emerging as a promising medicine for various mental disorders. Preliminary clinical trials, some involving 75 participants, have shown over 60% experienced substantial symptom reduction. This alkaloid, whether naturally derived or via chemical synthesis for Psychedelics and Drug Studies, influences neurotransmitter receptors, altering behavior. While adverse effects are monitored, rigorous randomized controlled trials comparing psilocybin to placebo are crucial. Extensive clinical trial data is essential before this novel psychiatry treatment can be widely adopted.
Abstract
Psilocybin - mostly combined with psychotherapy or psychotherapeutic support - shows a promise as a treatment for various (treatment-resistant) mental disorders. Larger double-blind RCTs with objective (long-term) outcomes are needed to confirm these findings before standard clinical use of psilocybin can be considered.